Home Biotechnology Industry News RPS Receives CLIA Waiver for New AdenoPlus™

RPS Receives CLIA Waiver for New AdenoPlus™

The U.S. Food and Drug Administration (FDA) announced today that AdenoPlus™ – an improved version of Rapid Pathogen Screening’s (RPS®) first point-of-care (POC) diagnostic test for conjunctivitis...

(PRWeb April 26, 2012)

Read the full story at http://www.prweb.com/releases/2012/4/prweb9441098.htm